The Board resolution dated July 31, 2019, Imexpharm Corporation approved the following issues:
- Total revenue: 564.1 billion dongs, reached 38.9% plan of 2019, increased 8.4% compared to the same period last year.
- Profit before tax: 86.3 billion dongs, reached 39.2% plan of 2019, increased 7.7% compared to the same period last year.
- Total revenue: 1,450 billion dongs
- Profit before tax: 220 billion dongs.